Insulet Corporation
PODDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Valued at $9.87B, PODD is a mid-cap name in its sector. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Market Cap
$9.87B
Beta
1.08
P/E (TTM)
26.64
P/E (Fwd)
18.45
EPS (TTM)
$5.34
EPS (Fwd)
$7.71
ROE
26.0%
ROA
9.7%
Cash
$534.9M
Total Debt
$948.4M
Free CF
$236.9M
52W Change
-56.3%
Annual Financials
Cash vs Debt
Where PODD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, PODD finished 19.50% below its 150-day moving average ($184.32) and 30.32% below its 200-day moving average ($212.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PODD overbought or oversold?
At the September 2, 2026 close, PODD's RSI(14) was 54.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Insulet Corporation carries $948.4M in total debt against $534.9M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $236.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 26.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.31B (2022) to $2.71B (2025), reflecting a 107% increase over the period.
Investors considering Insulet Corporation should weigh the typical risks associated with PODD's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PODD.